CD34+ CELLS
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
285 | ファンコニ貧血 | 11 |
285. ファンコニ貧血
臨床試験数 : 62 / 薬物数 : 93 - (DrugBank : 30) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 144
Showing 1 to 10 of 11 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04248439 (ClinicalTrials.gov) | July 15, 202020200715 | 24/1/202020200124 | Gene Therapy for Fanconi Anemia, Complementation Group A | A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects With Fanconi Anemia Subtype A A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ CellsTransduce ... | Fanconi Anemia Complementation Group A | Biological: RP-L102 | Rocket Pharmaceuticals Inc. | NULL | Recruiting | 1 Year | N/A | All | 5 | Phase 2 | United States |
2 | EUCTR2018-002502-31-GB (EUCTR) | 07/02/202020200207 | 08/10/201920191008 | A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype A A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ CellsTransduc ... | A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype A - FANCOLEN-II A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ CellsTransduc ... | Fanconi anemia (subtype A) MedDRA version: 20.0;Level: LLT;Classification code 10055206;Term: Fanconi's anemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Fanconi anemia (subtype A) MedDRA version: 20.0;Level: LLT;Classification code 10055206;Term: Fancon ... | Product Code: RP-L102 INN or Proposed INN: CD34+CELLS Other descriptive name: CD34+CELLS | Rocket Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 5 | Phase 2 | Spain;United Kingdom | ||
3 | NCT04069533 (ClinicalTrials.gov) | November 28, 201920191128 | 23/8/201920190823 | Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A | A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients With Fanconi Anemia Subtype A A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ CellsTransduc ... | Fanconi Anemia Complementation Group A | Biological: RP-L102 | Rocket Pharmaceuticals Inc. | NULL | Recruiting | 1 Year | 17 Years | All | 5 | Phase 2 | Spain |
4 | NCT03814408 (ClinicalTrials.gov) | January 11, 201920190111 | 14/1/201920190114 | A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype ... | A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects With Fanconi Anemia Subtype A A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ CellsTransduced ... | Fanconi Anemia Complementation Group A | Biological: RP-L102 | Rocket Pharmaceuticals Inc. | NULL | Active, not recruiting | 1 Year | 12 Years | All | 2 | Phase 1 | United States |
5 | EUCTR2018-002502-31-ES (EUCTR) | 31/10/201820181031 | 02/08/201820180802 | A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype A A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ CellsTransduc ... | A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype A - FANCOLEN-II A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ CellsTransduc ... | Fanconi anemia (subtype A) MedDRA version: 20.0;Level: LLT;Classification code 10055206;Term: Fanconi's anemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Fanconi anemia (subtype A) MedDRA version: 20.0;Level: LLT;Classification code 10055206;Term: Fancon ... | Product Name: RP-L102 INN or Proposed INN: CD34+CELLS Other descriptive name: CD34+CELLS | Rocket Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 5 | Phase 2 | Spain | ||
6 | NCT02678533 (ClinicalTrials.gov) | February 10, 201720170210 | 5/2/201620160205 | Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor Mobilization and Collection of Peripheral Blood Stem Cellsin Patients With Fanconi Anemia Using G-CS ... | Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy Pilot Study Assessing the Feasibility of CD34+ CellsMobilization and Collection After Treatment With ... | Fanconi Anemia | Drug: G-CSF;Drug: Plerixafor | Assistance Publique - Hôpitaux de Paris | EuroFancolen | Completed | 2 Years | 17 Years | All | 4 | Phase 1/Phase 2 | France |
7 | EUCTR2014-004272-29-GB (EUCTR) | 30/03/201520150330 | 15/07/201520150715 | Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent transduction with a lentiviral vector carrying the FANCA gene and reinfusion into the patient - Fancostem-Plerixafor & Filgrastim mobilisation in Fanconi Anaemia Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cell ... | Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent transduction with a lentiviral vector carrying the FANCA gene and reinfusion into the patient - Fancostem-Plerixafor & Filgrastim mobilisation in Fanconi Anaemia Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cell ... | Fanconi Anaemia;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Fanconi Anaemia;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and A ... | Trade Name: Mozobil Product Name: Mozobil INN or Proposed INN: Mozobil Other descriptive name: Plerixafor Trade Name: Neupogen Product Name: Neupogen INN or Proposed INN: Neupogen Other descriptive name: Filgrastim Trade Name: Mozobil Product Name: Mozobil INN or Proposed INN: Mozobil Other descriptive name: Plerixaf ... | Great Ormond Street Hospital NHS foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | France;Spain;United Kingdom | ||
8 | NCT02931071 (ClinicalTrials.gov) | September 201320130900 | 6/9/201620160906 | Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1 Clinical Phase II Trial to Evaluate CD34+ CellsMobilization and Collection in Patients With Fanconi ... | Clinical Phase II Trial to Evaluate Efficacy and Safety of CD34+ Cells Mobilization and Collection After Treatment With Plerixafor and Filgrastim in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene and Reinfusion in the Patient Clinical Phase II Trial to Evaluate Efficacy and Safety of CD34+ CellsMobilization and Collection Af ... | Fanconi Anemia | Drug: filgrastim;Drug: plerixafor | Hospital Universitari Vall d'Hebron Research Institute | CIEMAT;CIBERER | Completed | 2 Years | 64 Years | All | 13 | Phase 2 | Spain |
9 | EUCTR2011-006100-12-ES (EUCTR) | 12/04/201320130412 | 27/01/201220120127 | Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of cells transduced with a therapeutic lentiviral vector for patients with Fanconi Anemia Subtype A. Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of cellstransduced w ... | Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) for patients with Fanconi Anemia Subtype A. - Fancolen-1 Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ ... | Fanconi anemia (Subtype A) MedDRA version: 15.1;Level: LLT;Classification code 10055206;Term: Fanconi's anemia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Fanconi anemia (Subtype A) MedDRA version: 15.1;Level: LLT;Classification code 10055206;Term: Fancon ... | Product Name: CD34+ Cells INN or Proposed INN: CD34+ CELLS Other descriptive name: CD34+ CELLS | FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 5 | Phase 1 | Spain | ||
10 | NCT02127905 (ClinicalTrials.gov) | March 201120110300 | 19/10/201220121019 | Unrelated HSCT in Patients With Fanconi Anemia | A Study of Total Body Irradiation, Cyclophosphamide and Fludarabine Followed by Alternated Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia A Study of Total Body Irradiation, Cyclophosphamide and Fludarabine Followed by Alternated Donor Hem ... | Fanconi Anemia | Biological: CD34+ selected cells | Neena Kapoor, M.D. | NULL | Withdrawn | 8 Weeks | 21 Years | All | 0 | N/A | United States |